Otonomy, Inc.
OTIC
OTIC은(는) 2022년 12월 22일에 상장 폐지됐어요.
소개: Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
직원 수: 51
뉴스
OTIC에 대한 최신 뉴스 기사를 아직 받지 못했어요.